Information sent to healthcare professionals in June 2009 about the safety of medicines

Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.

A list of letters sent to healthcare professionals in June 2009, to inform of new safety information and advice.

Date issued Product Safety information
1 June 2009 ReFacto AF moroctocog alfa (recombinant coagulation factor VIII)

ReFacto AF is a successor product to ReFacto and is now available: information for discussion with staff and patients (third letter to have been sent as part of planned communications to support product launch).

› Letter for healthcare professionalsPDF file (opens in new window) (104Kb)
› Letter for laboratory directorsPDF file (opens in new window) (117Kb)
› Patient factsheetPDF file (opens in new window) (62Kb)
› Laboratory standard instruction sheetPDF file (opens in new window) (41Kb)
› Summary of Product Characteristics (SPC)PDF file (opens in new window) (193Kb)
› Summary of changes to SPCPDF file (opens in new window) (148Kb)
› Patient Information LeafletPDF file (opens in new window) (752Kb)
› New packagingPDF file (opens in new window) (2505Kb)
2 June 2009 CellCept (mycophenolate mofetil)PDF file (opens in new window) (431Kb) Cases of pure red cell aplasia
Commencing 24 June 2009 Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta)PDF file (opens in new window) (648Kb)

Production temporarily suspended: risk of delays in fulfilling orders and risk of potential therapy interruptions.
Communication of temporary treatment recommendations in light of supply shortage
29 June 2009 Neupro (rotigotine)

Lifting of supply and treatment restrictions

› Letter for healthcare professionalsPDF file (opens in new window) (48Kb)
› Letter for pharmacistsPDF file (opens in new window) (54Kb)


Page last modified: 07 July 2009